STRO vs. ADAP, FENC, CHRS, CADL, PSTX, GLUE, AGEN, MGX, IVVD, and CMPX
Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Adaptimmune Therapeutics (ADAP), Fennec Pharmaceuticals (FENC), Coherus BioSciences (CHRS), Candel Therapeutics (CADL), Poseida Therapeutics (PSTX), Monte Rosa Therapeutics (GLUE), Agenus (AGEN), Metagenomi (MGX), Invivyd (IVVD), and Compass Therapeutics (CMPX). These companies are all part of the "medical" sector.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.
Sutro Biopharma has higher revenue and earnings than Adaptimmune Therapeutics. Sutro Biopharma is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 6.9% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Sutro Biopharma had 11 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 23 mentions for Sutro Biopharma and 12 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of -0.06 beat Sutro Biopharma's score of -0.24 indicating that Sutro Biopharma is being referred to more favorably in the news media.
Adaptimmune Therapeutics presently has a consensus target price of $2.67, indicating a potential upside of 140.24%. Sutro Biopharma has a consensus target price of $12.50, indicating a potential upside of 211.72%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Adaptimmune Therapeutics.
Adaptimmune Therapeutics has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
Adaptimmune Therapeutics received 185 more outperform votes than Sutro Biopharma when rated by MarketBeat users. However, 64.74% of users gave Sutro Biopharma an outperform vote while only 62.47% of users gave Adaptimmune Therapeutics an outperform vote.
Sutro Biopharma has a net margin of -74.61% compared to Sutro Biopharma's net margin of -890.13%. Adaptimmune Therapeutics' return on equity of -94.18% beat Sutro Biopharma's return on equity.
Summary
Sutro Biopharma beats Adaptimmune Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Sutro Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sutro Biopharma Competitors List
Related Companies and Tools
